Bio – computational expertise

Bio – computational expertise 2016-10-24T15:19:24+00:00


Thanks to the work of Jerome Moreaux research team and in collaboration with the Institute for computational biomedicine (group of Olivier Elemento) (, Weill Cornell Institute, New York, the Research team has integrated GEP analysis platform and computational strategies to develop integrative, iterative and model-based strategy development for MM personalized medicine using Next Generation Sequencing data and called :


GenomicScape : Context

GenomicScape: What’s for?

GenomicScape: The tools

GenomicScape : conclusion

GenomicScape : Publications

  • Moreaux J, Reme T, Leonard W, et al. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol Cancer Ther. 2012;11(12):2685-2692.
  • Moreaux J, Reme T, Leonard W, et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer. 2013;109(3):676-685.
  • Moreaux J, Bruyer A, Veyrune JL, Goldschmidt H, Hose D, Klein B. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine. Br J Haematol. 2014;164(4):613-616.
  • Mahtouk K, Cremer FW, Reme T, et al. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene. 2006;25(54):7180-7191.
  • Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007.
  • Mahtouk K, Hose D, Reme T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene. 2005;24(21):3512-3524.
  • Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood. 2004;103(5):1829-1837.
  • Mahtouk K, Moreaux J, Hose D, et al. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC cancer. 2010;10:198.
  • Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106(3):1021-1030.
  • Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103(8):3148-3157.
  • Moreaux J, Sprynski A-C, Mahtouk K, et al. Binding of TACI and APRIL to Syndecan-1 Confer on Them a Major Role in Multiple Myeloma. ASH Annual Meeting Abstracts. 2007;110(11):3522-.
  • Moreaux J, Sprynski AC, Dillon SR, et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol. 2009;83(2):119-129.
  • Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113(19):4614-4626.
  • Sprynski AC, Hose D, Kassambara A, et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia. 2010;24(11):1940-1950.